BL-M07D1
Sponsors
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.
Conditions
Biliary Tract CancerBreast CancerCervical CancerEndometrial CancerEsophageal CancerGastric AdenocarcinomaGastric CancerGastroesophageal Junction Adenocarcinoma
Phase 1
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
RecruitingNCT05461768
Start: 2022-08-09End: 2027-12-31Target: 26Updated: 2025-09-26
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
RecruitingNCT05631964
Start: 2023-01-05End: 2027-12-31Target: 26Updated: 2025-09-26
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
RecruitingNCT06031584
Start: 2024-01-19End: 2026-03-31Target: 42Updated: 2025-08-03
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
RecruitingNCT06114511
Start: 2024-04-24End: 2026-04-30Target: 98Updated: 2025-08-03
A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
RecruitingNCT06131450
Start: 2024-02-29End: 2027-12-31Target: 138Updated: 2025-09-26
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingNCT06293898
Start: 2024-02-09End: 2029-04-15Target: 280Updated: 2026-03-23
Phase 2
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
RecruitingNCT06423885
Start: 2024-12-24End: 2026-10-31Target: 40Updated: 2025-08-06
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
RecruitingNCT06445400
Start: 2024-06-19End: 2026-06-30Target: 120Updated: 2025-08-03
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
RecruitingNCT06891833
Start: 2025-06-05End: 2028-12-31Target: 120Updated: 2025-10-02
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
RecruitingNCT07264816
Start: 2026-02-03End: 2027-12-01Target: 80Updated: 2026-03-05
Phase 3
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Active, not recruitingNCT06316531
Start: 2024-05-08End: 2026-05-31Updated: 2025-08-19
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
RecruitingNCT06830889
Start: 2025-06-03End: 2031-12-01Target: 1450Updated: 2026-01-22
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
RecruitingNCT06957886
Start: 2025-05-15End: 2027-12-01Target: 566Updated: 2026-01-21
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
RecruitingNCT07152405
Start: 2025-09-24End: 2027-06-30Target: 490Updated: 2025-11-17
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
RecruitingNCT07178795
Start: 2025-09-29End: 2027-12-31Target: 440Updated: 2025-11-17